Table 4.
Multiple regression analysis
| HR | 95% CI | p value | |
|---|---|---|---|
| PTH <150 pg/mL | |||
| Age, years | 1.062 | 1.014–1.130 | 0.010 |
| Hemoglobin, g/dL | 0.680 | 0.509–0.910 | 0.009 |
| Diabetes mellitus, % | 2.572 | 1.099–6.016 | 0.029 |
| ALP/100, IU/L | 1.598 | 1.249–2.045 | <0.001 |
| Use of CCBs, % | 0.343 | 0.153–0.769 | 0.009 |
| 150≤ PTH <300 pg/mL | |||
| Age, years | 1.056 | 1.025–1.087 | <0.001 |
| Female, % | 0.377 | 0.149–0.950 | 0.039 |
| CV disease, % | 1.874 | 1.059–3.318 | 0.031 |
| ALP/100, IU/L | 1.171 | 1.102–1.244 | <0.001 |
| CRP, mg/dL | 1.103 | 0.008–1.207 | 0.033 |
| PTH ≥300, pg/mL | |||
| Age, years | 1.057 | 1.031–1.084 | <0.001 |
| eGFR, mL/min/1.73 m2 | 1.196 | 1.003–1.426 | 0.046 |
| Use of CCBs, % | 0.494 | 0.271–0.899 | 0.021 |
Adjusted for sex, age, body mass index (BMI), diabetes mellitus, cardiovascular (CV) disease, estimated glomerular filtration rate (eGER), hemoglobin (Hb), albumin (Alb), alkaline phosphatase (ALP), parathyroid hormone (PTH), phosphorus, C-reactive protein (CRP), calcium channel blockers (CCB). HR, hazard ratio; CI, confidence interval.